

Market Outlook

The Nifty 50 closed at 25,910, witnessing some selling pressure from the 26,000 mark amid an ongoing consolidation phase. On the daily chart, the 25,800 level is expected to act as an immediate support, and sustaining above this zone will help maintain the prevailing bullish sentiment. For the monthly expiry, derivatives data indicates fresh Call OI build-up at the 26,000 strike, highlighting it as an immediate hurdle. On the downside, immediate support lies in the 25,800–25,700 zone, while strong support is placed at the 25,500 level.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25910.05	-0.40
SENSEX	84673.02	-0.33
BANKNIFTY	58899.25	-0.11
INDIA VIX	12.09	2.61

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	116.52	0.16%
Index Options	7919.09	-34.45%
Stock Futures	-2440.31	0.04%
Stock Options	-160.09	1.75%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-728.42	-13939	-124159
DII	6156.83	48974	491424

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
TATASTEEL	18862691	4.08	21.54
HDFCBANK	13276284	-1.49	8.73
ETERNAL	13121054	1.6	-6.18
POWERGRID	11718569	-1.73	66.26
TMPV	10081221	9.86	-46.02
BEL	7187406	-2.09	2.65
AXISBANK	6855922	6.65	148.92
BHARTIARTL	6330430	-8.97	82.91
RELIANCE	5992310	-0.1	88.12
ICICIBANK	5696159	-17.04	24.4


NIFTY

Nifty	25948.80
OI (In contracts)	269575
CHANGE IN OI (%)	-0.90
PRICE CHANGE (%)	-0.40
IMPLICATION	LONG UNWINDING

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
PGEL	585	0.40	15991	9.90
CONCOR	521.85	1.00	30658	6.30
SHRIRAMFIN	822.5	0.20	68768	3.40
BIOCON	422.9	0.30	21020	3.30
HUDCO	243.66	1.90	12684	3.10


BANKNIFTY

Banknifty	58974.60
OI (In contracts)	58328
CHANGE IN OI (%)	1.10
PRICE CHANGE (%)	-0.10
IMPLICATION	SHORT BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
MPHASIS	2666.5	-0.80	25997	55.90
KAYNES	5911.5	-5.70	23922	28.50
IREDA	148.19	-2.00	13487	13.90
TMPV	371.15	-0.30	109674	7.20
INOXWIND	140.91	-3.90	26209	7.20

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
VOLTAS	5444250	4445250	1.22
CANBK	147663000	125604000	1.18
ANGELONE	2727000	2473000	1.1
PETRONET	16011000	14493600	1.1
NATIONALUM	39780000	37788750	1.05
AUROPHARMA	4875750	4719000	1.03
POWERINDIA	286750	281400	1.02
AUBANK	6852000	6843000	1
BPCL	19349075	19503125	0.99
PGEL	8888600	9120300	0.97

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
KAYNES	1254700	3930900	0.32
ONGC	19037250	58932000	0.32
SHREECEM	58450	184475	0.32
NESTLEIND	2037500	6093500	0.33
FORTIS	4054025	11460700	0.35
TATASTEEL	122171500	352847000	0.35
PAGEIND	67680	182355	0.37
APOLLOHOSP	1012750	2646375	0.38
INOXWIND	18801034	48870592	0.38
BOSCHLTD	76225	194050	0.39

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2473	2503	2457	2428	2411
ADANIPORTS	1513	1529	1503	1488	1477
APOLLOHOSP	7481	7569	7429	7341	7289
ASIANPAINT	2916	2934	2892	2874	2850
AXISBANK	1277	1288	1263	1252	1238
BAJAJ-AUTO	8984	9047	8947	8884	8847
BAJAJFINSV	2071	2090	2060	2041	2029
BAJFINANCE	1023	1031	1018	1010	1005
BEL	427	433	424	419	415
BHARTIARTL	2169	2188	2140	2121	2092
CIPLA	1531	1545	1523	1509	1501
COALINDIA	388	391	386	383	381
DRREDDY	1248	1254	1241	1234	1227
EICHERMOT	6863	6909	6812	6766	6716
ETERNAL	311	316	308	303	300
GRASIM	2787	2812	2771	2746	2730
HCLTECH	1605	1616	1597	1587	1579
HDFCBANK	998	1002	995	990	987
HDFCLIFE	769	775	765	759	755
HINDALCO	808	817	799	790	781
HINDUNILVR	2422	2435	2414	2402	2394
ICICIBANK	1381	1388	1377	1371	1366
INDIGO	5850	5949	5797	5698	5645
INFY	1503	1517	1495	1481	1473
ITC	408	410	407	405	403

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	311	315	308	304	301
JSWSTEEL	1176	1187	1166	1156	1146
KOTAKBANK	2105	2115	2094	2084	2073
LT	4035	4068	4007	3974	3946
M&M	3727	3751	3710	3685	3668
MARUTI	16027	16127	15899	15799	15671
MAXHEALTH	1138	1157	1127	1108	1096
NESTLEIND	1272	1279	1264	1257	1249
NTPC	330	331	329	327	326
ONGC	249	251	248	246	245
POWERGRID	277	279	275	272	270
RELIANCE	1529	1537	1520	1512	1503
SBILIFE	2013	2029	2003	1987	1977
SBIN	976	980	973	970	967
SHRIRAMFIN	830	838	821	813	804
SUNPHARMA	1768	1777	1760	1750	1742
TATACONSUM	1173	1189	1164	1148	1139
TATASTEEL	174	175	172	171	170
TCS	3101	3113	3091	3078	3068
TECHM	1444	1463	1433	1414	1404
TITAN	3907	3932	3875	3850	3818
TMPV	374	376	371	369	367
TRENT	4411	4442	4388	4357	4334
ULTRACEMCO	11801	11875	11753	11679	11631
WIPRO	244	246	242	240	238

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results